Dosing Begins in Phase 2 Trial of 3K3A-APC to Protect Patients’ Neurons

Dosing Begins in Phase 2 Trial of 3K3A-APC to Protect Patients’ Neurons

313712

Dosing Begins in Phase 2 Trial of 3K3A-APC to Protect Patients’ Neurons

A Phase 2 trial of ZZ Biotech’s investigational therapy 3K3A-APC in people with amyotrophic lateral sclerosis (ALS) has started dosing patients at its single site in Australia, the company announced in a press release. The open-label trial (NCT05039268), underway at the Macquarie University in Sydney, aims to evaluate the safety and tolerability as well as the potential effectiveness of 3K3A-APC in 16 adults diagnosed in the last two years. It is currently enrolling eligible patients; contact information…

You must be logged in to read/download the full post.